Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | C1R | P00736 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799754 | 0.85 | PDPK1 (0.38) | PDPK1ELANEALDH1A1GRM2BACE1 | |
| SCHEMBL30592385 | 0.80 | ADORA3 (0.41) | ALDH1A1NQO2PARP1ACHEKDM4E | |
| SCHEMBL2320859 | 0.80 | ADORA3 (0.41) | ALDH1A1NQO2PARP1ACHEKDM4E | |
| SCHEMBL9954808 | 0.77 | NPC1 (0.39) | ALDH1A1NQO2PARP1ACHEKMT2A | |
| SCHEMBL6422445 | 0.77 | ADRA2A (0.40) | ALDH1A1BACE1NQO2ACHEKDM4E | |
| SCHEMBL11842508 | 0.77 | ALDH1A1 (0.50) | ALDH1A1NQO2PARP1ACHEKMT2A | |
| SCHEMBL31180566 | 0.77 | NQO2 (0.43) | ALDH1A1BACE1NQO2PARP1ACHE | |
| SCHEMBL14486329 | 0.75 | NQO2 (0.36) | ALDH1A1GRM2NQO2 | |
| SCHEMBL24276712 | 0.74 | NQO2 (0.50) | PDPK1ALDH1A1BACE1NQO2ACHE | |
| SCHEMBL15228704 | 0.74 | TDP1 (0.52) | PDPK1ELANEALDH1A1GRM2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024149189-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | PDPK1 1459/4885ELANE 1245/4885ALDH1A1 898/4885 |
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | PDPK1 199/4885ELANE 3284/4885ALDH1A1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.